|
Carbimazole
drug data and news
Carbimazole drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Carbimazole
|
| Brand Names/Synonyms |
Athyromazole; Atirozidina; Basolest; CG1; Carbethoxymethimazole; Carbimazol; Carbimazol Spofa; Carbimazol [Inn-Spanish, French]; Carbimazole; Carbimazole [Ban:Dcf:Inn]; Carbimazolum [Inn-Latin]; Carbinazole; Carbotiroid; Mertiran; Neo-Mercazole; Neo-Thyreostat; Neo-Tireol; Neomercazole; Tyrazol |
| Indication |
For the treatment of hyperthyroidism; Thyrotoxicosis; It is also used to prepare patients for thyroidectomy. |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
|
| Mechanism Of Action |
Carbimazole is an aitithyroid agent that decreases the uptake and concentration of inorganic iodine by thyroid, it also reduces the formation of di-iodotyrosine and thyroxine. |
Carbimazole News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Tablet |
| Drug_Category |
Antithyroid Agents; ATC:H03BB01 |
| Absorption |
Not Available |
| Interactions |
Interactions for Carbimazole:
Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect
of Carbimazole.
Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents. A decrease of the
dosage may be necessary when patient becomes euthyroid.
Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days
after sudden withdrawal of Carbimazole.
Patient's response to oral anticoagulants may be affected by his/her thyroid and metabolic status. An evaluation of prothrombin
time and an adjustment of anticoagulant dosage are recommended
|
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
ethyl 3-methyl-2-sulfanylidene-1,3-dihydroimidazole-1-carboxylate |
| Chemical Formula |
C7H10N2O2S |
| Molecular Weight |
186.233 g/mol |
| Smiles String |
CCOC(=O)N1C=CN(C1=S)C |
| Melting Point |
123.5 °C |
| Water Solubility |
Not Available |
| State |
Solid |
| LogP/Hphobicity |
0.842 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
Not Available |
| Protein Binding [%] |
85% |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00503 |
| CAS Registry Number |
22232-54-8 |
| KEGG Compound ID |
C07615 |
| PubChem ID |
SID:354231 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
